WebNews
Please enter a web search for web results.
NewsWeb
The Cognitive Penalty of ECT Has Always Been Its Ceiling " MST Just Removed It
21+ hour, 1+ min ago (524+ words) The Clinical Trial Vanguard The Cognitive Penalty of ECT Has Always Been Its Ceiling " MST Just Removed It A patient I've been treating for three years " severe, recurrent MDD, failed four antidepressants, failed esketamine, partial responder to ketamine infusions " finally…...
Five Approvals, Nine Expansions: What the EMA's April CHMP Meeting Reveals About Where Global Drug Development Is Heading
20+ hour, 57+ min ago (121+ words) That asymmetry deserves scrutiny before anyone calls it progress. Which raises the uncomfortable question sponsors are not publicly asking: how many of those nine extensions represent genuine therapeutic advancement versus market protection for molecules approaching patent cliffs? The CHMP does…...
Structure to Present New Diabetes Combination Data at ADA
21+ hour, 55+ min ago (593+ words) The Clinical Trial Vanguard Structure to Present New Diabetes Combination Data at ADA Structure Therapeutics will take an oral small-molecule GLP-1 receptor agonist into the ADA spotlight with Phase 2b ACCESS data for aleniglipron billed as delivering meaningful weight reductions, alongside…...
FDA Fast Tracks Scancell's Melanoma Drug After Phase 2 Data
21+ hour, 52+ min ago (598+ words) The Clinical Trial Vanguard FDA Fast Tracks Scancell's Melanoma Drug After Phase 2 Data Progression-free survival reached 77% at 20 months in the target HLA-selected population of Scancell's Phase 2 SCOPE trial when i SCIB1+ was added to ipilimumab plus nivolumab. That compares with 43% PFS…...
Bioxodes" BIOX-101 Shows Breakthrough ICH Trial Results
21+ hour, 55+ min ago (605+ words) The Clinical Trial Vanguard Bioxodes" BIOX-101 Shows Breakthrough ICH Trial Results Final results from BIRCH, a 23-patient multicenter, randomized, open-label Phase 2a trial in spontaneous intracerebral hemorrhage, met the primary safety endpoint and showed exploratory signals of efficacy, including reduced hematoma…...
BIOMEDE Missed Its Primary Endpoint " And Still Changed Pediatric CNS Trial Design Forever
1+ day, 18+ hour ago (573+ words) The Clinical Trial Vanguard BIOMEDE Missed Its Primary Endpoint " And Still Changed Pediatric CNS Trial Design Forever Picture a trial statistician in 2026 opening a Phase 2 readout for diffuse intrinsic pontine glioma " one of the most lethal pediatric brain tumors on…...
When the Vendor Consolidates, Sites Feel It First
1+ day, 23+ hour ago (846+ words) The Clinical Trial Vanguard When the Vendor Consolidates, Sites Feel It First A site coordinator opening a new contract package does not think about vendor consolidation strategy. She thinks about the redlines she sent three weeks ago that nobody has…...
KOL Event Spotlights Lasofoxifene for Resistant Cancer
4+ day, 21+ hour ago (664+ words) Phase 2 signals continue to support lasofoxifene's pursuit of ESR1mutated, ER+/HER2 metastatic breast cancer. In ELAINE1, lasofoxifene outperformed fulvestrant with a median progressionfree survival of 5. 6 months versus 3. 7 months and a higher objective response rate (13. 3% versus 2. 9%), including a complete response lasting more than 2. 5 years....
Neonc Technologies Announces Updated Clinical Trial Results
4+ mon, 6+ day ago (151+ words) In an expanded 25-patient Phase 1/2a plus compassionate-use cohort of recurrent WHO Grade III/IV IDH1-mutant astrocytoma, intranasal NEO100 produced a 24% radiographic remission rate (6/25), six-month progression-free survival of 44%, and 36% of patients alive at or beyond 18 months from treatment start. No significant toxicity…...
Nectero Reports 2-Year Safety and Efficacy Data for AAA
4+ day, 21+ hour ago (618+ words) The Clinical Trial Vanguard Nectero Reports 2-Year Safety and Efficacy Data for AAA In a 46-patient first-in-human study of small- to medium-sized abdominal aortic aneurysms (AAA), Nectero's investigational Nectero EAST System delivered a median aneurysm diameter growth of 1. 00 mm per…...